Vyvanse Shortage Guide for Healthcare Providers: Alternatives, Protocols, and Patient Communication

The ongoing Vyvanse (lisdexamfetamine) shortage continues to create real clinical challenges for prescribers across the country. This guide gives you a practical, up-to-date framework for managing your ADHD patients through the shortage — covering therapeutic alternatives, switching protocols, prior authorization strategy, patient communication, and how tools like FindUrMeds can reduce the administrative burden on your practice.

---

The Current Vyvanse Shortage: What Prescribers Need to Know

Vyvanse has been on the FDA's drug shortage list on and off since 2022, when the surge in ADHD diagnoses — accelerated in part by pandemic-era telehealth expansion — outpaced the supply chain's ability to keep up. The problem is compounded by DEA production quotas on Schedule II controlled substances, which limit how much lisdexamfetamine manufacturers can produce in any given year.

As of 2024–2025, the generic form of lisdexamfetamine (approved after Vyvanse's exclusivity expired) has expanded availability somewhat, but shortages remain inconsistent across regions and pharmacy chains. A patient in one zip code may fill their prescription without issue while another across town hits a wall.

Key factors driving the shortage:

• DEA annual aggregate production quotas (AAPQs) on Schedule II stimulants
• High demand from both pediatric and adult ADHD populations
• Inconsistent distribution across retail pharmacy chains
• Limited specialty pharmacy access in some regions
• Post-pandemic ADHD diagnosis growth outpacing manufacturing scale-up

The practical result: your patients are calling your office frustrated, pharmacies are turning them away, and your staff is spending time they don't have tracking down alternatives.

---

Therapeutic Alternatives to Vyvanse: A Clinical Overview

Switching a patient who is stable on Vyvanse isn't always straightforward. Lisdexamfetamine is a prodrug — it's converted to d-amphetamine after oral ingestion, which gives it a gradual onset and lower abuse potential compared to immediate-release amphetamines. That pharmacokinetic profile matters clinically. Keep that in mind when evaluating alternatives.

Amphetamine-Based Alternatives

Mixed amphetamine salts XR (Adderall XR) or generic equivalents The most commonly considered substitute. Adderall XR contains 75% d-amphetamine salts and 25% l-amphetamine salts. The clinical effect is similar but not identical. Patients may notice a sharper onset or shorter duration compared to Vyvanse. Note: Adderall XR has also experienced shortage periods — confirm availability before switching.

Approximate dose conversion (use clinical judgment):

• Vyvanse 30 mg → Adderall XR ~10–15 mg
• Vyvanse 50 mg → Adderall XR ~20 mg
• Vyvanse 70 mg → Adderall XR ~30 mg

These are rough starting points, not exact equivalencies. Titrate based on individual response.

Mixed amphetamine salts IR (Adderall IR) Some patients may actually prefer IR dosing for flexibility, though twice-daily dosing can be harder to adhere to. Consider this for patients who need an afternoon "booster" effect or have trouble swallowing capsules.

Dextroamphetamine (Dexedrine or generic) Purely d-amphetamine, available in both IR and spansule (extended-release) form. A reasonable alternative if mixed salts aren't available either. Less commonly stocked but worth checking.

Non-Amphetamine Alternatives

Methylphenidate-based medications (Concerta, Ritalin LA, Focalin XR, Quillivant XR) A reasonable therapeutic class switch, particularly for patients with cardiac concerns that preclude higher amphetamine doses, or for those who haven't previously failed methylphenidate. Onset of action and duration will differ. Patients should be counseled to expect an adjustment period.

Atomoxetine (Strattera) A non-stimulant option appropriate for patients where stimulants are contraindicated, or for those who can't get a Schedule II prescription refilled in a timely way. Takes 4–6 weeks for full effect — not a practical bridge for acute shortage situations, but worth discussing for long-term planning.

Viloxazine (Qelbree) A newer non-stimulant option (FDA-approved for ADHD in children 6–17, and adults). Less clinical history than atomoxetine but growing in use. Not a controlled substance, which means no DEA quota constraints.

Alpha-2 agonists (guanfacine ER, clonidine ER) Typically used as adjuncts or for patients with comorbid tics, anxiety, or oppositional symptoms. Can be used as bridges or add-ons during shortage periods.

---

Switching Protocols: Clinical Considerations

When you do need to switch a patient, a few principles will make the transition smoother:

1. Document the shortage, not just the clinical rationale. In your chart, note that the switch is driven by medication unavailability. This creates a clear record if a patient has a suboptimal response and you need to justify returning to Vyvanse later.

2. Treat it like a new titration — not a simple substitution. Even if the pharmacology is similar, individual responses vary. Start at the lower end of the dose conversion range and titrate up based on response and tolerability, particularly in children, adolescents, and patients with cardiovascular history.

3. Monitor more closely during the transition. A 2–3 week follow-up (by phone or portal is fine) gives you a chance to catch efficacy gaps or side effects before they escalate into nonadherence.

4. Consider behavioral strategies as a bridge. For patients who will be without medication for a short period (a few days to a week), a brief conversation about non-pharmacological strategies — structured routines, task chunking, minimizing distractions — can reduce anxiety and functional disruption.

5. Pediatric patients and adolescents need extra attention. Academic performance, behavior, and family dynamics can shift quickly when ADHD medication is disrupted. Loop in parents and, when appropriate, the school if an extended transition is expected.

---

Prior Authorization Considerations During Shortages

Switching medications often triggers a new prior authorization (PA) process, and this is one of the most frustrating friction points for prescribers managing shortage-related switches.

What to expect:

• Many insurers require step therapy — they want to see that the patient has tried cheaper alternatives before approving Vyvanse or branded products
• Generics, once available, are almost always preferred by payers
• PAs for brand-name Vyvanse may be denied if the generic lisdexamfetamine is available in your region, even if it's not locally in stock

Practical tips:

• Document shortage specifics. When submitting a PA or appealing a denial, include specific documentation that the alternative is unavailable — not just that the patient prefers the original medication. Pharmacy notes showing "out of stock" or "unable to source" are useful supporting evidence.
• Appeal medical necessity when warranted. If a patient has a specific reason they need Vyvanse (e.g., documented failure on the alternative, a formulation reason, or a comorbidity), build that case in the PA paperwork.
• Use manufacturer assistance programs during PA delays. Takeda's patient assistance programs and copay cards may apply while PAs are being processed for commercially insured patients.
• Set realistic timelines with your staff. PA appeals for stimulants can take 1–3 weeks. Factor that into your transition planning.

For more information on helping patients navigate cost and insurance barriers, see how to help patients save money on Vyvanse.

---

Communicating With Patients About the Shortage

How you frame the shortage matters as much as the clinical plan. Patients — especially adults managing their own ADHD — can feel dismissed or anxious when their medication becomes unavailable. A few communication principles that help:

Be direct and factual. Explain that this is a nationwide supply problem, not a problem with their pharmacy or their prescription. Many patients assume they've done something wrong or that their prescriber dropped the ball.

Give them a plan, not just news. "Here's what we're going to try" lands much better than "there's nothing we can do." Even if the plan is imperfect, patients respond better when they feel like they have agency.

Acknowledge the disruption. ADHD is not a lifestyle inconvenience — it affects work, relationships, parenting, and academics. Validating that the shortage is genuinely disruptive builds trust and keeps patients engaged with their care.

Give them practical tools. Pointing patients to resources that can help them locate their medication removes a burden from your office and gives patients something actionable. Services like FindUrMeds how to help patients find Vyvanse in stock can search across 15,000+ pharmacies nationwide, which is often more effective than a patient calling four or five pharmacies on their own.

---

Using FindUrMeds as a Provider Resource

If you're a prescriber dealing with shortage-related calls, you know how much staff time goes into "pharmacy hunting." FindUrMeds is a pharmacy locator service that contacts pharmacies on behalf of patients to find their prescription in stock — typically within 24–48 hours, across 15,000+ locations including CVS, Walgreens, Walmart, Rite Aid, Kroger, Publix, Costco, and Sam's Club.

How it helps your practice:

• Reduces inbound calls from patients who can't find their medication
• Gives staff a reliable first step to recommend before escalating to an alternative medication
• Trusted by 200+ healthcare providers nationally
• 92% success rate in locating in-stock prescriptions

You can recommend FindUrMeds directly to patients as a self-service resource. They simply submit their medication information online, and FindUrMeds handles the pharmacy outreach. It won't replace your clinical decision-making, but it can dramatically reduce the administrative friction that shortages create for your office.

---

Frequently Asked Questions From Providers

Is lisdexamfetamine generic considered therapeutically equivalent to brand Vyvanse?

Yes. Generic lisdexamfetamine is rated AB-equivalent to brand Vyvanse by the FDA, meaning it has demonstrated bioequivalence in pharmacokinetic studies. Most clinical guidelines and payers treat them as interchangeable. Where patients report differences, it's often related to inactive ingredients, which can affect tolerability in sensitive individuals.

Can I write a brand-name-only prescription to prevent generic substitution?

Yes, you can write "dispense as written" (DAW) or "brand medically necessary," but insurers may not cover brand Vyvanse if a generic equivalent is available, leaving patients with significantly higher out-of-pocket costs. Discuss the tradeoffs with your patient before defaulting to this approach.

How do I handle a patient who refuses to switch and is running out of medication?

First, validate the concern. Then, separate the two problems: (1) can we help them find their current medication, and (2) what's the backup plan if we can't? Services like FindUrMeds may locate the medication without a switch being necessary. If a switch is unavoidable, involve the patient in choosing the alternative — shared decision-making improves adherence even in non-ideal situations.

Is there a way to flag my patient panel for shortage-related issues proactively?

Some EHR systems allow alert tagging, but there's no universal system for shortage flagging at the prescriber level. Practically, many practices are managing this by having front desk staff note when a patient calls about a Vyvanse shortage and flagging them for a follow-up message with a resource list and alternative options. Proactive outreach — before patients call in crisis — tends to reduce inbound volume overall.

---

Need help finding Vyvanse in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Vyvanse Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →